FDA Vulnerable To Meddling In Climate Of Distrust – Commish Hamburg
This article was originally published in The Rose Sheet
Executive Summary
An atmosphere of distrust in government makes FDA vulnerable to congressional meddling, Commissioner Margaret Hamburg suggested in a July 25 presentation to consumer group Public Citizen.
You may also be interested in...
FDA Thinking "Seriously, Deeply" About Range Of Approval Strategies – Hamburg
FDA is considering further “modulations” of its current approaches to drug approvals in order to encourage innovation and get products to market more quickly, Commissioner Margaret Hamburg commented during a panel session at the Biotechnology Industry Organization International Convention in Washington, D.C. on June 28.
House Cuts WIC Funding In Appropriations Bill
The House passes a fiscal 2012 appropriations bill with significant cuts to a program that provides infant formula for low-income women.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.